{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:03:38Z","timestamp":1778504618924,"version":"3.51.4"},"reference-count":27,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emergence of new chelators is likely to have a major impact on the treatment of thalassemia major, sickle cell disease and other hematologic disorders for which regular red cell transfusions are required either to correct severe anemia or to prevent major complications of the underlying disease. In comparison with deferoxamine, which requires prolonged parenteral infusion to achieve negative iron balance, orally active chelators offer the promise of easier administration and better compliance. Moreover, the availability of more than one iron chelator opens up the possibility of combination therapy to target iron in specific organs and to enhance overall iron excretion. Long-term studies, employing new technologies to measure tissue iron, are required to determine whether the new chelators will be as safe and effective as deferoxamine in maintaining control of iron stores and preventing iron-induced cardiac disease, the major complication of transfusional iron overload.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.42","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"42-47","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["New Advances in Iron Chelation Therapy"],"prefix":"10.1182","volume":"2006","author":[{"given":"Alan R.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111702500162600_R1","unstructured":"Borgna-Pignatti C, Rugolotto S, DeStefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187\u20131193."},{"key":"2019111702500162600_R2","doi-asserted-by":"crossref","unstructured":"Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26\u201336.","DOI":"10.1159\/000203853"},{"key":"2019111702500162600_R3","doi-asserted-by":"crossref","unstructured":"Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127:348\u2013355.","DOI":"10.1111\/j.1365-2141.2004.05202.x"},{"key":"2019111702500162600_R4","doi-asserted-by":"crossref","unstructured":"Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229\u20131236.","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236"},{"key":"2019111702500162600_R5","doi-asserted-by":"crossref","unstructured":"Davis BA, O\u2019Sullivan, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263\u2013269.","DOI":"10.1182\/blood-2003-08-2841"},{"key":"2019111702500162600_R6","doi-asserted-by":"crossref","unstructured":"Olivieri NF, Loren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990;336:1275\u20131279.","DOI":"10.1016\/0140-6736(90)92962-H"},{"key":"2019111702500162600_R7","doi-asserted-by":"crossref","unstructured":"Collins AF, Fassos FF, Stobie S, et al. Iron balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83:2329\u20132333.","DOI":"10.1182\/blood.V83.8.2329.2329"},{"key":"2019111702500162600_R8","doi-asserted-by":"crossref","unstructured":"Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial. Br J Haematol.1992;82:460\u2013466.","DOI":"10.1111\/j.1365-2141.1992.tb06445.x"},{"key":"2019111702500162600_R9","unstructured":"Grady RW, Berdoukas V, Rachmilewitz EA, et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion [abstract]. Blood. 2002;100:241."},{"key":"2019111702500162600_R10","doi-asserted-by":"crossref","unstructured":"Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17\u201324.","DOI":"10.1182\/blood-2002-06-1867"},{"key":"2019111702500162600_R11","doi-asserted-by":"crossref","unstructured":"Olivieri NF, Brittenham GM, Matsui, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918\u2013922.","DOI":"10.1056\/NEJM199504063321404"},{"key":"2019111702500162600_R12","doi-asserted-by":"crossref","unstructured":"Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417\u2013423.","DOI":"10.1056\/NEJM199808133390701"},{"key":"2019111702500162600_R13","doi-asserted-by":"crossref","unstructured":"Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F: Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583\u20131587.","DOI":"10.1182\/blood-2002-10-3280"},{"key":"2019111702500162600_R14","doi-asserted-by":"crossref","unstructured":"Maggio A, D\u2019Amico GD, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cell Mol Dis. 2002;28:196\u2013208.","DOI":"10.1006\/bcmd.2002.0510"},{"key":"2019111702500162600_R15","doi-asserted-by":"crossref","unstructured":"Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361\u2013364.","DOI":"10.1046\/j.1365-2141.1998.01002.x"},{"key":"2019111702500162600_R16","doi-asserted-by":"crossref","unstructured":"Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cell Mol Dis. 2006;36:21\u201325.","DOI":"10.1016\/j.bcmd.2005.11.002"},{"key":"2019111702500162600_R17","doi-asserted-by":"crossref","unstructured":"Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance [Abstract]. Blood. 2006;106:1017a.","DOI":"10.1182\/blood.V106.11.3655.3655"},{"key":"2019111702500162600_R18","doi-asserted-by":"crossref","unstructured":"Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741\u20132748.","DOI":"10.1182\/blood.V79.10.2741.2741"},{"key":"2019111702500162600_R19","doi-asserted-by":"crossref","unstructured":"Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in \u03b2-thalassaemia\/haemoglobin E patients in Thailand. Br J Haematol. 2003;122:305\u2013310.","DOI":"10.1046\/j.1365-2141.2003.04412.x"},{"key":"2019111702500162600_R20","doi-asserted-by":"crossref","unstructured":"Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in \u03b2 thalassaemia. Lancet. 2002;360:516\u2013520.","DOI":"10.1016\/S0140-6736(02)09740-4"},{"key":"2019111702500162600_R21","unstructured":"Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489\u2013496."},{"key":"2019111702500162600_R22","doi-asserted-by":"crossref","unstructured":"Borgna-Pignatti C, Cappellini MD, DeStefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733\u20133737.","DOI":"10.1182\/blood-2005-07-2933"},{"key":"2019111702500162600_R23","doi-asserted-by":"crossref","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738\u20133744.","DOI":"10.1182\/blood-2005-07-2948"},{"key":"2019111702500162600_R24","doi-asserted-by":"crossref","unstructured":"Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597\u20131602.","DOI":"10.1016\/S0140-6736(03)13309-0"},{"key":"2019111702500162600_R25","doi-asserted-by":"crossref","unstructured":"Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with \u03b2 thalassemia. Blood. 2006;107:3455\u20133462.","DOI":"10.1182\/blood-2005-08-3430"},{"key":"2019111702500162600_R26","doi-asserted-by":"crossref","unstructured":"Vichinsky E, Fischer R, Fung E, et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade\u00ae, ICL670) is well tolerated and reduces iron burden [Abstract]. Blood. 2005;106:95a.","DOI":"10.1182\/blood.V106.11.313.313"},{"key":"2019111702500162600_R27","doi-asserted-by":"crossref","unstructured":"Greenberg P, Dine G, Ganser A, et al. Deferasirox (Exjade\u00ae, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia [Abstract] Blood. 2005;106:757a.","DOI":"10.1182\/blood.V106.11.2694.2694"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/42\/1091687\/042_047ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/42\/1091687\/042_047ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T01:24:58Z","timestamp":1628126698000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/42\/19817\/New-Advances-in-Iron-Chelation-Therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.42","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}